Canine Intranasal Adenocarcinoma Study in Dogs

The University of Illinois is currently enrolling patients in a multicenter, randomized, double-masked, placebo-controlled clinical trial to evaluate a novel investigational product in dogs with stage 3 intranasal adenocarcinoma.

Trial Eligibility:
We are enrolling dogs that meet the following criteria:

- Dog is ≥ 12 months of age
- Dog weighs > 5kg
- Dog has ECOG performance status less ≤ 1
- Dog has stage 3 intranasal adenocarcinoma and is amenable to radiotherapy
- Dog is able to tolerate multiple anesthesia events
- No radiotherapy, chemotherapy, or surgical therapy prior to enrollment
- No clinically significant cardiovascular arrhythmias

* Other study inclusion and exclusion criteria apply. The veterinary investigator will decide if the dog is a good candidate for this study after examination. *

Study Information:
The study is a “controlled” study, which means that some dogs receive treatment and others receive a placebo. The treatment or placebo tables will be administered prior to each radiotherapy treatment.

This study is also “masked,” meaning that neither you nor the veterinarian making observations will know if your dog received the treatment.

Participation Requirements:
Qualified dogs will receive radiation therapy and investigational product or placebo intravenously under general anesthesia for 5 consecutive days. Dogs and owners will be required to visit study site for regularly scheduled appointments over a 4-month period and document study associated observations and questionnaires as appropriate.

Study Benefits:
This is a partially funded clinical trial.

For additional information regarding the study, please contact Rebecca Kamerer at rmoss81@illinois.edu or 217-300-6453.